postoperative pain market insight

DelveInsight’s ‘Postoperative Pain-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the postoperative pain, historical and forecasted epidemiology as well as the postoperative pain market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Postoperative Pain market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM postoperative pain market size from 2018 to 2030. The Report also covers current postoperative pain treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Postoperative Pain Disease Understanding and Treatment Algorithm

Postoperative Pain Overview

Postoperative Pain is an anticipated and temporary increase in background pain that occurs following surgical procedures. It is a type of pain that typically lasts less than a few days to months or pain directly related to soft tissue damage such as a sprained ankle or a paper cut. The pain is of short duration, but it gradually resolves as the injured tissues heal. It is further classified as acute and chronic pain based on the duration.

The Interagency Pain Research Coordinating Committee (IPRCC) of the US Department of Health and Human Services describes acute pain as “an expected physiologic experience to noxious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.”

The intensity, quality, and duration of postoperative pain are affected mainly by the location, type, and duration of the surgical procedure; type and extent of the incision and surgical trauma; the physical and mental state of the patient including the patient’s approach to pain; preoperative psychological and pharmacological preparation; type of anesthesia; pain management before and after the surgical procedure; incidence of surgical complications; and quality of postoperative care.

Postoperative Pain Diagnosis

In order to treat pain efficiently, it needs to be properly diagnosed, measured, and documented. Only by this, optimal analgesia may be achieved, which is a mild and tolerable sensation of pressure in the surgical wound with minimal adverse effects. Proper diagnosis of the type and intensity of pain is crucial for an adequate and targeted treatment of acute pain. It requires a highly professional approach in terms of expertise, psychology, and ethics. The examination of acute postoperative pain involved medical history, physical examination, and specific evaluation of pain; measuring pain; rating scales provide a simple means for patients to rate pain intensity; verbal expression to assess the intensity of pain and other assessments.

Continued in the report…..

Postoperative Pain Treatment

Postoperative pain management aims not only to decline pain intensity but also to increase patient comfort and to improve postoperative outcomes. Pharmacologic therapies for pain include drugs from several drug classes. Pain-relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, and acetaminophen. Providers also elect to manage acute pain with benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. Topical agents, such as capsaicin and lidocaine are also used.

Nonpharmacologic therapies for pain are becoming more widely used to avoid problems associated with pharmacologic therapies. Examples of nonpharmacologic therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM).

Continued in the report…..

Postoperative Pain Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total number of surgical procedures, total number of incident cases of postoperative pain, and severity-specific incident cases of postoperative pain scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Key Findings

• In the 7MM, the total number of incident cases of postoperative pain was 66,426,881 in 2020.
• In 2020, the US reported the highest number of surgical procedures with 50,773,111, while the EU5 countries accounted for 16,948,543 surgical procedures. Japan ranked second among 7MM countries with 15,311,947 surgical procedures in 2020.
• Among 7MM, the US reported the highest number of incident cases of postoperative pain, i.e. 40,618,489 in 2020.
• According to DelveInsight, in 2020, it is estimated that the severity-specific incident cases in the US were 12,388,639; 18,075,228 and 10,154,622 for mild, moderate, and severe postoperative pain, respectively.
• Among the EU5, Germany had the highest cases of postoperative pain, i.e. 4,107,445 cases, followed by France which had 3,625,643 cases in 2020. On the other hand, Spain had the lowest incident cases of postoperative pain, i.e. 1,428,080.
• In 2020, Japan accounted for 12,249,558 incident cases of postoperative pain which is second-highest after the US among 7MM countries.

Country Wise Postoperative Pain Epidemiology

The epidemiology segment also provides the Postoperative pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Postoperative Pain Drug Chapters

The drug chapter segment of the Postoperative pain report encloses the detailed analysis of Postoperative pain marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Postoperative pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Postoperative Pain Marketed Drugs

Exparel: Pacira Pharmaceuticals

Exparel (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired period.

Products detail in the report…

Anjeso: Baudax Bio

ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. Anjeso (meloxicam) injection was approved by the US Food and Drug Administration (FDA) in February 2020 for use in adults to manage moderate to severe pain, alone or in combination with non-NSAID analgesics. Because of the delayed onset of analgesia, Anjeso alone is not recommended for use when a rapid onset of analgesia is required.

Products detail in the report…

Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals

Dsuvia is an opioid agonist that contains sufentanil and is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. Dsuvia is administered in the form of the tablet sublingually to the patient. However, the intensity of pain must be severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It was approved in 2018 in the US and EU for the management of moderate-to-severe acute pain in medically supervised settings for adult patients. In January 2021, AcelRx announced an investigator-initiated study with University Hospitals Cleveland Medical Center to evaluate the postoperative use of the drug in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol.

Products detail in the report…

List to be continued in the report…

Postoperative Pain Emerging Drugs

CR845/Difelikefalin: Cara Therapeutics

Cara Therapeutics is developing the first peripherally acting kappa opioid receptor agonist (KORA) called CR845. The drug is a potent peripheral kappa-opioid receptor agonist with high selectivity over other opioid receptors in the body. The degree of kappa receptor selectivity displayed by CR845 is best-in-class compared to all other previously developed compounds for this therapeutic target.

Products detail in the report…

VVZ-149 Injections: Vivozon, Inc.

Vivozon, Inc. is developing VVZ-149, a drug with a new mechanism-based nonnarcotic and non-NSAID analgesic. VVZ-149 is currently being evaluated in clinical trials (Korea and USA) in an IV infusion setting to treat postoperative pain following laparoscopic gastrectomy or laparoscopic colorectomy and lumbar radiculopathy (Sciatica). The company is preparing a comprehensive data package to initiate the GLP toxicology studies of the oral VVZ-149.

Products detail in the report…

F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell

The MedinCell’s partner, Arthritis Innovation Corporation (AIC)’s drug F14 (sustained-release celecoxib)/ mdc-CWM (Celecoxib), is an extended-release intra-articular injectable drug for postoperative pain and inflammation treatment in clinical testing which uses sustained local delivery of an NSAID after total knee replacement (TKR) to manage pain and inflammation as an alternative to oral NSAIDs or narcotics

Products detail in the report…

List to be continued in the report…

Postoperative Pain Market Outlook

The United States holds a major share of the postoperative pain market as compared to other countries of the 7MM.

The effective relief of pain is of the utmost importance to treating patients undergoing surgery. Pain relief has significant physiological benefits; hence, monitoring of pain relief is increasingly becoming a crucial postoperative quality measure. The goal for postoperative pain management is to reduce or eliminate pain and discomfort with a minimum of side effects. In recent years, extensive changes have been observed in the postoperative pain management market. Opioid replacement with other more beneficiary approaches has been in talk. Opioid was a gold standard but is now being replaced by multimodal analgesia (MMA) models. Even several top agencies like the US Department of Health and Human Services (USDHHS) are showing their primary focus in multimodal pain management. MMA helps to increase efficacy while minimizing adverse effects since different targets are approached with lesser doses. In ambulatory patient care also MMA model is capable of achieving adequate pain relief to discharge the patient earlier.

In spite of the growing awareness of the value of multimodal pain management plans, opioid monotherapy remains the foundation of postsurgical pain therapy. Opioids that are delivered by the patient-controlled analgesia are the support of systemic analgesia for the treatment of moderate-to-severe postoperative pain. Analgesics that act by different mechanisms and at various receptor sites are normally combined to produce additive or synergistic pain relief and can reduce opioid use. Regimens that use nonopioid analgesics include paracetamol, NSAIDs (cyclo-oxygenase inhibitors), alpha 2 agonists (clonidine, dexmedetomidine), gabapentin, pregabalin, Ketamine, Lignocaine infusions, and Peripheral nerve blocks, local anesthetic wound infiltration, and continuous wound infusion techniques.

Pain relief after surgery continues to be a major medical challenge. Poorly managed postoperative pain may delay discharge and recovery, and result in the patient's inability to participate in rehabilitation programs, leading to poor outcomes. There is a major unmet need for the recent advances that include a better understanding of pain mechanisms, physiology, and pharmacology, the publication of guidelines, establishment of acute pain services (APSs), initiatives such as ‘pain as the fifth vital sign’ and availability of new drugs and devices. However, these advances have not led to any major improvements, and the under-treatment of postoperative pain continues as a considerable problem worldwide. Overall, the postoperative pain therapeutics market is further expected to increase in the forecast period (2021–2030).

Key Findings

• The therapeutic market of postoperative pain in the 7MM was USD 2,570 million in 2020.
• The therapeutic market of postoperative pain in the United States was USD 2,223 million in the year 2020.
• The current market of postoperative pain is mainly covered by Opioids, NSAIDS/Corticosteroids, Anesthetics, and. In 2020, the market size of Exparel was USD 397 million in the 7MM.
• The market size in the 7MM might increase at a CAGR of 7.93%. An increase in the number of surgeries, advancement in the current and emerging treatment of postoperative pain, are the primary factors driving the growth of the postoperative pain market.
• Posimir (Bupivacaine Solution), Olinvyk (oliceridine), Zalviso (sufentanil), and others—pipeline candidates—are expected to enter the market in the forecasted period (2021–2030). There are many therapies that are going to increase the overall market that includes, Anjeso (Meloxicam). Korsuva (CR845), Co-crystal E-58425 (Tramadol/Celecoxib), Zalviso (sufentanil), and Tramadol IV. Besides, Zynrelef (bupivacaine and meloxicam), Posimir (Bupivacaine Solution), and Olinvyk (oliceridine) are anticipated to get launched in 2021.
• Among EU5 countries, Germany captured the highest market with USD 65 million in 2020, followed by France and the UK. Whereas Spain captured the least market size with USD 21 million in 2020.
• The therapeutic market of postoperative pain in Japan was USD 139 million in the year 2020.

The United States Market Outlook

This section provides the total postoperative pain market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total postoperative pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total postoperative pain market size and market size by therapies in Japan are provided.

Postoperative Pain Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the postoperative pain market or expected to get launched in the market during the study period 2018–2030. The analysis covers postoperative pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postoperative Pain Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Postoperative pain emerging therapies.

Reimbursement Scenario in Postoperative Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Postoperative pain market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of postoperative pain, explaining its pathophysiology, diagnosis, and available therapies.
• Comprehensive insight has been provided into postoperative pain epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for postoperative pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the postoperative pain market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM postoperative pain market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the postoperative pain market.
• The companies and academics are working to assess challenges and seek opportunities that could influence postoperative pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for postoperative pain. The launch of emerging therapies will significantly impact the postoperative pain market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Postoperative Pain Report Insights

• Patient Population
• Therapeutic Approaches
• Postoperative pain Pipeline Analysis
• Postoperative pain Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Postoperative Pain Report Key Strengths

• 10-Years Forecast
• 7MM Coverage
• Postoperative pain Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Postoperative Pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions

Market Insights:

• What was the postoperative pain market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the postoperative pain total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest postoperative pain market size during the forecast period (2021–2030)?
• At what CAGR, the postoperative pain market is expected to grow at the 7MM level during the forecast period (2021–2030)?
• What would be the postoperative pain market outlook across the 7MM during the forecast period (2021–2030)?
• What would be the postoperative pain market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of postoperative pain?
• What is the historical postoperative pain patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of postoperative pain at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to postoperative pain?
• Out of the above-mentioned countries, which country would have the highest incident population of postoperative pain during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of postoperative pain along with the approved therapy?
• What are the current treatment guidelines for the treatment of postoperative pain in the US and Europe?
• What are the postoperative pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of postoperative pain?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of postoperative pain?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the postoperative pain therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for postoperative pain and their status?
• What are the key designations that have been granted for the emerging therapies for postoperative pain?
• What are the 7MM historical and forecasted market of postoperative pain?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving postoperative pain.
• To understand the future market competition in the postoperative pain market and an insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for postoperative pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the postoperative pain market.
• To understand the future market competition in the postoperative pain market.